Zydus Lifesciences Ltd.
BSE: 532321 | NSE: ZYDUSLIFE
Mid Cap | Pharmaceuticals & Drugs
930.60
-16.50 (-1.74%) Zydus Lifesciences informs about press release
Date: 09-09-2022Zydus Lifesciences has informed that it enclosed copy of press release dated September 9, 2022 titled ‘Zydus in-licenses a critical drug for CKD patients from Pharmacosmos A/S of Denmark’.
The above information is a part of company’s filings submitted to BSE.